Hong-Ryul Jung
Research Subjects
Hong-Ryul Jung has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Akash Das
ORIC Pharmaceuticals, Inc., South San Francisco, California
13 shared publications - Alexander I. Spira
Virginia Cancer Specialists Research Institute, Fairfax, VA
13 shared publications - Anneleen Daemen
Department of Bioinformatics & Computational Biology, Genentech, Inc
13 shared publications - Ashley S. Pereira
ORIC Pharmaceuticals, Inc., South San Francisco, California
13 shared publications - Brenda Chan
ORIC Pharmaceuticals, Inc., South San Francisco, California
13 shared publications - Brian R. Blank
ORIC Pharmaceuticals, Inc., South San Francisco, California
13 shared publications
Latest Publications
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig S4 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Figure S4 shows brain penetrance and intracranial efficacy in preclinical models
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig S4 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Figure S4 shows brain penetrance and intracranial efficacy in preclinical models
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Table S4 shows the mutational landscape of EGFR mutant PDX models
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Table S4 shows the mutational landscape of EGFR mutant PDX models
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig S5 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Figure S5 shows pharmacodynamic effect of enozertinib on EGFR Protein
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig S5 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Figure S5 shows pharmacodynamic effect of enozertinib on EGFR Protein
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 2 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Supplementary Data 2 shows the variant allele frequency (VAF) of patient
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 2 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Supplementary Data 2 shows the variant allele frequency (VAF) of patient
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data 1 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Supplementary Data 1 sows GENIEv15.1 EGFR mutation analysis
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data 1 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Supplementary Data 1 sows GENIEv15.1 EGFR mutation analysis
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Data from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
EGFR mutations are common oncogenic drivers in non–small cell lung cancer (NSCLC), and approximately half of patients develop brain metastases over the course of their disease. Patients with nonclassic EGFR mutations, such as insertions in exon 20, are a high unmet need with a worse prognosis compared with patients with classic EGFR mutations. Here, we describe the discovery and development of enozertinib (formerly ORIC-114), a highly brain-penetrant, orally bioavailable, irreversible inhibitor that targets EGFR exon 20 mutations with unparalleled kinome selectivity. Preclinical studies revealed strong potency and tumor regressions driven by enozertinib across a broad range of atypical EGFR-mutant models. In a phase I clinical trial of enozertinib in patients with advanced NSCLC bearing atypical mutations in EGFR, a patient harboring an EGFR exon 20 insertion experienced sustained complete response of all systemic and brain metastases. Together, these findings identify enozertinib as a promising investigational inhibitor to address the unmet need for brain-penetrant therapies in NSCLC with EGFR exon 20 insertions or other atypical mutations.Significance:Preclinical and initial phase I clinical data demonstrate the potency, kinome selectivity, efficacy, and brain penetration of enozertinib in NSCLC with EGFR exon 20 insertions and atypical mutations, warranting further clinical development.
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
EGFR mutations are common oncogenic drivers in non–small cell lung cancer (NSCLC), and approximately half of patients develop brain metastases over the course of their disease. Patients with nonclassic EGFR mutations, such as insertions in exon 20, are a high unmet need with a worse prognosis compared with patients with classic EGFR mutations. Here, we describe the discovery and development of enozertinib (formerly ORIC-114), a highly brain-penetrant, orally bioavailable, irreversible inhibitor that targets EGFR exon 20 mutations with unparalleled kinome selectivity. Preclinical studies revealed strong potency and tumor regressions driven by enozertinib across a broad range of atypical EGFR-mutant models. In a phase I clinical trial of enozertinib in patients with advanced NSCLC bearing atypical mutations in EGFR, a patient harboring an EGFR exon 20 insertion experienced sustained complete response of all systemic and brain metastases. Together, these findings identify enozertinib as a promising investigational inhibitor to address the unmet need for brain-penetrant therapies in NSCLC with EGFR exon 20 insertions or other atypical mutations.Significance:Preclinical and initial phase I clinical data demonstrate the potency, kinome selectivity, efficacy, and brain penetration of enozertinib in NSCLC with EGFR exon 20 insertions and atypical mutations, warranting further clinical development.
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Figure S3 shows EGFR WT-sparing ratios in cellular assays
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Figure S3 shows EGFR WT-sparing ratios in cellular assays
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Table S2 shows the biochemical potency of enozertinib and other EGFR inhibitors across mutant EGFR proteins
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Table S2 shows the biochemical potency of enozertinib and other EGFR inhibitors across mutant EGFR proteins
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig S1 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Figure S1 shows the discovery of enozertinib
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig S1 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Figure S1 shows the discovery of enozertinib
- Open Access
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
SupplementaryFig S2 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Figure S2 shows biochemical potency of enozertinib compared to other EGFR inhibitors.
- 2 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementaryFig S2 from Enozertinib Is a Selective, Brain-Penetrant EGFR Inhibitor for Treating Non–Small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations
Figure S2 shows biochemical potency of enozertinib compared to other EGFR inhibitors.